Proliferation News and Research

RSS

Meningiomas likely results from hemodynamic changes associated with pregnancy

Meningiomas are a common type of benign brain tumor that sometimes grows dramatically in pregnant women. A new study suggests that this sudden tumor growth likely results from "hemodynamic changes" associated with pregnancy, reports the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

21 Nov 2012

Researchers discover new cause of hydrocephalus

Researchers at the University of Iowa have discovered a new cause of hydrocephalus, a devastating neurological disorder that affects between one and three of every 1,000 babies born. Working in mice, the researchers identified a cell signaling defect, which disrupts immature brain cells involved in normal brain development.

20 Nov 2012

Scientists identify cell growth pathway that is unusually active in gliomas

Insights from a genetic condition that causes brain cancer are helping scientists better understand the most common type of brain tumor in children.

17 Nov 2012

D737 compound restores motor function and longevity in fruit flies with Alzheimer's

An efficient, high-volume technique for testing potential drug treatments for Alzheimer's disease uncovered an organic compound that restored motor function and longevity to fruit flies with the disease, according to new research that could help put the search for an effective Alzheimer's drug on a faster track.

16 Nov 2012

Researchers discover unlikely recipe to kill antibiotic resistant bacteria

Washington State University researchers have found an unlikely recipe for antibiotic resistant bacteria: Mix cow dung and soil, and add urine infused with metabolized antibiotic. The urine will kill off normal E. coli in the dung-soil mixture. But antibiotic-resistant E. coli will survive in the soil to recolonize in a cow's gut through pasture, forage or bedding.

16 Nov 2012

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

A group of researchers at the University of California, Berkeley have for the first time described the structure of the active site core of topoisomerase II alpha, an important target for anti-cancer drugs.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary.

15 Nov 2012

Semprus BioSciences to develop surface-modified endotracheal tube

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced that Semprus BioSciences, a wholly owned subsidiary of Teleflex Incorporated, has been awarded the initial phase of a $2.3 million research grant from the U.S. Army's Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, MD.

9 Nov 2012

Glycemic load raises colon cancer recurrence risk

Increased glycemic loads and high carbohydrate consumption may increase the risk for colon cancer recurrence, show the results of a US study.

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

Carbohydrate-rich food intake may cause recurrence of colon cancer

Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.

8 Nov 2012

London School of Hygiene & Tropical Medicine creates International Diagnostics Centre

Today sees the launch of the International Diagnostics Centre (IDC), a global research collaboration hub, created at the London School of Hygiene & Tropical Medicine to undertake innovative research on the development and deployment of new diagnostic tests that enable patients to be diagnosed faster, more accurately and cost effectively.

8 Nov 2012

Scientists show how sorafenib can be dangerous to the heart

Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Fracture bracing systems: an interview with Steve Ingel, President for the Bracing & Supports Division of DJO Global

Surprisingly, there are significantly more medical treatment episodes for upper extremity fractures than for those of lower extremity. The vast majority of forearm, hand and wrist fractures occur in pediatrics and young adults as they tend to be more active and involved in sporting activities.

6 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

3 Nov 2012

CD22 protein could prove to be important new target for anti-cancer therapy

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time.

2 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Proliferation News and Research

Meningiomas likely results from hemodynamic changes associated with pregnancy

Researchers discover new cause of hydrocephalus

Scientists identify cell growth pathway that is unusually active in gliomas

D737 compound restores motor function and longevity in fruit flies with Alzheimer's

Researchers discover unlikely recipe to kill antibiotic resistant bacteria

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

Semprus BioSciences to develop surface-modified endotracheal tube

Glycemic load raises colon cancer recurrence risk

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Carbohydrate-rich food intake may cause recurrence of colon cancer

London School of Hygiene & Tropical Medicine creates International Diagnostics Centre

Scientists show how sorafenib can be dangerous to the heart

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Fracture bracing systems: an interview with Steve Ingel, President for the Bracing & Supports Division of DJO Global

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

CD22 protein could prove to be important new target for anti-cancer therapy

Nisin may slow or prevent squamous cell head and neck cancers

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Latest News